FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1. Visit OXLUMO.com for more information, including full Prescribing Information.
52 
Let's personalize your content